HUYABIO International Announces Pivotal Data for HBI-8000 in Advanced Melanoma Selected for Late-Breaking Presentation at ESMO Congress 2026
Presentation in oral Proffered Paper session follows positive topline Phase 3 data showing a statistically significant improvement in median progression-free survival in advanced melanoma patients when HBI-8000 was combined with nivolumab vs immunotherapy alone
SAN DIEGO, Sept. 29, 2026 /PRNewswire/ -- HUYABIO International, the leader in accelerating the development of innovative biopharmaceutical products discovered in China, announced today that further data from its pivotal phase 3 trial of HBI-8000 in combination with nivolumab in advanced melanoma has been selected as a Late-Breaking Abstract (LBA) and will be presented in an oral Proffered Paper session at ESMO Congress 2026 taking place Oct. 23 - 27 in Madrid, Spain.
HBI-8000 is a highly differentiated oral selective Class I histone deacetylase (HDAC) inhibitor designed to boost the immune response against cancer cells through epigenetic modification. By modifying the tumor microenvironment from non-responsive ('cold') to responsive ('hot'), HBI-8000 has the potential to enhance the activity of anti-PD-1 checkpoint inhibitors such as nivolumab.
HUYABIO announced topline results from the global Phase 3 trial in July which showed a statistically significant improvement in median progression-free survival (mPFS) in advanced melanoma patients taking HBI-8000 and nivolumab compared with those taking nivolumab plus placebo. The randomized global Phase 3 trial enrolled 404 patients across 15 countries.
The abstract will be available on the ESMO website at 00:05 CET on Friday, October 23.
Details of the ESMO Congress 2026 presentation
Abstract Number: LBA54 - Primary Analysis of HBI-8000-303: A Randomized Phase 3 Trial of Nivolumab plus HBI-8000 or Placebo in Advanced Melanoma
Presenter: Nikhil I. Khushalani, Moffitt Cancer Center, Tampa, FL, USA
Proffered Paper Session Details: Friday, October 23 at 16:15 - 17:45 CET in Barcelona Auditorium - Hall 9
About HUYABIO International
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in international markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, Europe, and China, the company has become a partner of choice to accelerate product development and maximize patient impact and value globally.
For more information, visit www.huyabio.com.
About HBI-8000
HBI-8000 (tucidinostat/chidamide) is potentially the best-in-class immuno-modulator. It is a highly differentiated oral, Class I-selective histone deacetylase (HDAC) inhibitor with an immunomodulatory mechanism. Through epigenetic modification, HBI-8000 has anti-tumor activity and converts an immunologically "cold" tumor microenvironment "hot", thereby increasing responsiveness to checkpoint inhibitors. HBI-8000 is approved and has been prescribed to over 112,000 patients as monotherapy for the treatment of T-cell lymphoma in China (as Epidaza ®) and Japan (as HIYASTA®), and in combination with an aromatase inhibitor for breast cancer in China and Taiwan, and in combination with R-CHOP in diffuse large B-cell lymphoma in China.
About the Phase 3 HBI-8000-303 trial
HBI-8000-303 [NCT04674683] is a global multicenter, randomized, double-blind, placebo-controlled Phase 3 study comparing the efficacy and safety of HBI-8000 combined with nivolumab to placebo combined with nivolumab in patients with unresectable or metastatic melanoma. The trial has completed enrollment and topline results were released in July 2026.
Media Contact:
SOURCE HUYABIO International
Share this article